# American Healthcare REIT, Inc.: overview

AHR · NYSE · CIK 1632970 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ahr.md) · [Financials](/companies/ahr/financials.md) · [Filings](/companies/ahr/filings.md) · [Insiders](/companies/ahr/insiders.md)

Latest reported revenue: [$634.5m](/filings/0001193125-26-340269.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-340269).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [477](/filings/0001193125-25-272390.md) | [497 d](/filings/0001193125-26-082692.md) | [497](/filings/0001193125-26-214678.md) | [501](/filings/0001193125-26-340269.md) | [532](/filings/0001193125-25-272390.md) | [564 d](/filings/0001193125-26-082692.md) | [610](/filings/0001193125-26-214678.md) | [635](/filings/0001193125-26-340269.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [19.6%](/filings/0001193125-25-272390.md) | [20.0% d](/filings/0001193125-26-082692.md) | [19.0%](/filings/0001193125-26-214678.md) | [20.6%](/filings/0001193125-26-340269.md) | [19.9%](/filings/0001193125-25-272390.md) | [19.8% d](/filings/0001193125-26-082692.md) | [20.6%](/filings/0001193125-26-214678.md) | [21.6%](/filings/0001193125-26-340269.md) |
| Net margin | % | [(0.9%)](/filings/0001193125-25-272390.md) | [(6.4%) d](/filings/0001193125-26-082692.md) | [(1.4%)](/filings/0001193125-26-214678.md) | [2.0%](/filings/0001193125-26-340269.md) | [10.5%](/filings/0001193125-25-272390.md) | [1.9% d](/filings/0001193125-26-082692.md) | [3.9%](/filings/0001193125-26-214678.md) | [4.8%](/filings/0001193125-26-340269.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001193125-25-272390.md) | not reported | [(0.04)](/filings/0001193125-26-214678.md) | [0.06](/filings/0001193125-26-340269.md) | [0.33](/filings/0001193125-25-272390.md) | not reported | [0.13](/filings/0001193125-26-214678.md) | [0.16](/filings/0001193125-26-340269.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,124](/filings/0001632970-24-000039.md) | [1,412](/filings/0001632970-25-000018.md) | [1,669](/filings/0001193125-26-082692.md) | [1,884](/filings/0001193125-26-082692.md) | [2,095](/filings/0001193125-26-082692.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [19.0%](/filings/0001632970-24-000039.md) | [21.4%](/filings/0001632970-25-000018.md) | [18.4%](/filings/0001193125-26-082692.md) | [19.3%](/filings/0001193125-26-082692.md) | [19.8%](/filings/0001193125-26-082692.md) |
| Net margin | % | [(4.3%)](/filings/0001632970-24-000039.md) | [(5.8%)](/filings/0001632970-25-000018.md) | [(4.3%)](/filings/0001193125-26-082692.md) | [(2.0%)](/filings/0001193125-26-082692.md) | [3.3%](/filings/0001193125-26-082692.md) |
| Diluted EPS | $ per share | [(0.95)](/filings/0001632970-24-000039.md) | [(1.24)](/filings/0001632970-25-000018.md) | [(1.08)](/filings/0001193125-26-082692.md) | [(0.29)](/filings/0001193125-26-082692.md) | [0.42](/filings/0001193125-26-082692.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ahr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.35bn | 25,845,948 |  | Reduced −2,895,146 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $885.3m | 16,975,438 |  | Added +851,414 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $479.9m | 9,201,599 |  | Added +1,002,975 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $474.0m | 9,046,025 |  | Reduced −499,019 |
| [PRINCIPAL FINANCIAL GROUP INC](/funds/1126328.md) | 2026-06-30 | $465.1m | 8,917,875 |  | Added +1,494,669 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $451.6m | 8,658,850 |  | Added +375,063 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $274.6m | 5,264,667 |  | Reduced −1,514,101 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $238.2m | 4,568,191 |  | Reduced −496,180 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $238.1m | 4,563,939 |  | Reduced −1,626,612 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $236.3m | 4,531,958 |  | Added +1,295,366 |

## Recent filings

[All 848 filings](/companies/ahr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-18 | 20:25 ET | [8-K](/filings/0001193125-26-395604.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-395604 |
| 2026-09-14 | 10:35 ET | [8-K](/filings/0001193125-26-389802.md) | 7.01 Regulation FD disclosure | 0001193125-26-389802 |
| 2026-09-02 | 21:22 ET | [8-K](/filings/0001193125-26-380473.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-380473 |
| 2026-09-01 | 20:29 ET | [8-K](/filings/0001193125-26-378483.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-378483 |
| 2026-08-24 | 20:16 ET | [8-K](/filings/0001193125-26-363616.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-363616 |
| 2026-08-12 | 20:16 ET | [8-K](/filings/0001193125-26-346895.md) | 8.01 Other events | 0001193125-26-346895 |
| 2026-08-10 | 20:06 ET | [8-K](/filings/0001193125-26-342358.md) | 1.01 Entry into a material agreement | 0001193125-26-342358 |
| 2026-08-07 | 20:15 ET | [10-Q](/filings/0001193125-26-340269.md) | Quarterly report, period 2026-06-30 | 0001193125-26-340269 |
| 2026-08-06 | 20:17 ET | [8-K](/filings/0001193125-26-338076.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-338076 |
| 2026-07-22 | 20:16 ET | [8-K](/filings/0001193125-26-312419.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-312419 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-082692.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4fb2ffe8-4dc9-449d-9ee3-629a7d98bff3)

## About the filer

- CIK: 1632970
- Tickers: AHR
- Exchange: NYSE
- SIC code: 6798 Real Estate Investment Trusts
- State of incorporation: MD
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.